{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/luts-in-men/prescribing-information/desmopressin/","result":{"pageContext":{"chapter":{"id":"ae12d520-87b4-5400-8cfa-79a25bb39663","slug":"desmopressin","fullItemName":"Desmopressin","depth":2,"htmlHeader":"<!-- begin field f4c2b91a-e852-43ee-a4af-c7215d62bbf8 --><h2>Desmopressin</h2><!-- end field f4c2b91a-e852-43ee-a4af-c7215d62bbf8 -->","summary":"","htmlStringContent":"<!-- begin item 703bff98-1ac3-4df6-8a45-718fd04a0fb1 --><!-- end item 703bff98-1ac3-4df6-8a45-718fd04a0fb1 -->","topic":{"id":"fdcce69d-578e-5994-a7c2-84be40932dd8","topicId":"a7bf3f2d-1d9e-47c0-9dd3-26731c4d092b","topicName":"LUTS in men","slug":"luts-in-men","lastRevised":"Last revised in March 2019","chapters":[{"id":"149361eb-636f-59a5-a2e2-b067d629a065","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c7972342-637c-56a9-8783-c1e8314e7fd1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7105be47-f38b-5335-b14d-69db43326579","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c8165ab8-59af-557d-824d-58f09041698f","slug":"changes","fullItemName":"Changes"},{"id":"776566d2-009e-5ebd-ac21-e5605029213a","slug":"update","fullItemName":"Update"}]},{"id":"4c1332b1-3f4f-530f-bb70-d627804caa79","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d434ba09-30c6-5bfc-bb6f-87e952a1b33a","slug":"goals","fullItemName":"Goals"},{"id":"702b01d3-71e8-5daf-a985-3935596391f5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0aef110d-14b4-5ae2-9da0-a07cc4aef9ef","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fcf6ae7-162e-5b90-84fb-2a79f82d420e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1c91c138-4e44-571e-8ac0-8e62f8dca310","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4fe99a13-4e80-5c28-b091-216c8a8d7f82","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3a98397f-2bc4-5e01-90d6-03d6fbe400c8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d41a85e2-c1cb-5198-afc7-7c4fbe28ae24","slug":"definitions","fullItemName":"Definitions"},{"id":"fd0f4942-31d6-517a-a10b-d341e34a2504","slug":"causes-of-luts","fullItemName":"Causes of LUTS"},{"id":"3af3e2a4-26b3-5a77-9e8b-3d393388e624","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1c6eecc6-b753-5918-adae-dc2d864d88fa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1432aa0-7841-5eec-85c4-e344d4629bd9","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"762c13bd-ead4-5aa6-b460-701b0572f9aa","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8874a841-31e1-5356-a3f6-7bff9c28c693","slug":"assessment","fullItemName":"Assessment"},{"id":"8c77fb91-6134-565b-b1ef-4452e83c424f","slug":"investigations","fullItemName":"Investigations"}]},{"id":"60ffa7b7-da40-599a-bffa-e6e68db76a97","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d790431-a0c8-5ca1-8143-be639ea2ec02","slug":"voiding-symptoms","fullItemName":"Scenario: Voiding symptoms"},{"id":"b1451e1b-3776-5aa0-94b0-79be5fb01831","slug":"overactive-bladder","fullItemName":"Scenario: Overactive bladder"},{"id":"f4818005-dc3a-52b2-ac5d-d14f0d6ac0db","slug":"nocturnal-polyuria","fullItemName":"Scenario: Nocturnal polyuria"},{"id":"fb3acb54-4d76-5aad-ab1c-7b0b3d9443a3","slug":"stress-urinary-incontinence","fullItemName":"Scenario: Stress urinary incontinence"},{"id":"c511bb10-1198-548d-8e23-a1f6e98df926","slug":"urinary-retention","fullItemName":"Scenario: Urinary retention"},{"id":"0a3e83b8-a00f-520f-b21f-9ef6cc6440e7","slug":"post-micturition-dribble","fullItemName":"Scenario: Post-micturition dribble"}]},{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c9f3458-4ae7-5003-a4f9-ed026a61a3d0","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"2f32bd76-64d1-51c9-bc96-4173829de1b5","slug":"5-alpha-reductase-inhibitors","fullItemName":"5-alpha reductase inhibitors"},{"id":"d7f3eec1-9124-5d3a-a793-15707f8cfeda","slug":"antimuscarinics","fullItemName":"Antimuscarinics"},{"id":"507e078b-b3d0-527c-b71d-0b1101948c01","slug":"mirabegron","fullItemName":"Mirabegron"},{"id":"7c2851da-6e40-5415-ada7-7466766510fa","slug":"furosemide","fullItemName":"Furosemide"},{"id":"ae12d520-87b4-5400-8cfa-79a25bb39663","slug":"desmopressin","fullItemName":"Desmopressin"}]},{"id":"dca797b5-427f-5ed5-94e4-3ad565f628a9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5e289c42-8089-5739-9683-20c374967578","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"07accac1-c375-54a3-92cc-d2cd8a2bb914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c05a5332-4c79-595e-b066-09dcd9841073","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8e5cf2cc-d3d4-5d7d-82a7-3dd1ae3c65d9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47ea76bd-52d3-5c5a-8d1f-f574eec081bd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"38a45d79-a74f-5ca9-a844-f16ea2c0ab75","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b3152db-f873-5814-b35f-54711f247dff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"3a8f17b0-65b0-5f98-ae74-7889d10f77ff","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 472c0055-6c05-40e8-a916-5e35afe933d1 --><h3>What are the contraindications and cautions for desmopressin?</h3><!-- end field 472c0055-6c05-40e8-a916-5e35afe933d1 -->","summary":"","htmlStringContent":"<!-- begin item 22b3a139-7b1b-46a1-b83c-730971b2f854 --><!-- begin field 991b7c68-f21c-498b-a87a-8e410ecf9c52 --><ul><li><strong>Do not prescribe desmopressin:</strong><ul><li>To people with:<ul><li>Cardiac insufficiency.</li><li>Conditions treated with diuretics.</li><li>Psychogenic polydipsia or alcohol abuse.</li><li>Known history of hyponatraemia. </li><li>Syndrome of inappropriate antidiuretic hormone secretion.</li></ul></li><li>For primary nocturnal enuresis and nocturia associated with multiple sclerosis in people aged over 65 years.</li></ul></li><li><strong>Prescribe desmopressin with caution in:</strong><ul><li>People with:<ul><li>Asthma.</li><li>Cardiovascular disease (not indicated for nocturnal enuresis or nocturia).</li><li>Conditions which might be aggravated by water retention.</li><li>Cystic fibrosis.</li><li>Hypertension (not indicated for nocturnal enuresis or nocturia).</li><li>Epilepsy.</li><li>Migraine.</li><li>Nocturia or nocturnal enuresis — limit fluid intake to minimum from 1 hour before dose until 8 hours afterwards.</li><li>Renal impairment — antidiuretic effect may be reduced.</li></ul></li><li>Elderly people (age 65 years and older) — they are at increased risk of hyponatraemia and renal impairment. The manufacturer advises that in elderly men [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2016c</a>]:<ul><li>Daily doses above 50 micrograms should not be used.</li><li>Serum sodium levels should be monitored before initiating treatment, in the first week of treatment (4–8 days after initiation) and again at one month after treatment initiation. Desmopressin treatment should be discontinued if the serum sodium level falls below the lower limit of normal range (135 mmol/L).</li><li>Treatment should be reviewed if there is no therapeutic benefit after 3 months.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]</p><!-- end field 991b7c68-f21c-498b-a87a-8e410ecf9c52 --><!-- end item 22b3a139-7b1b-46a1-b83c-730971b2f854 -->","subChapters":[]},{"id":"42b4b297-c6b8-5359-b0a0-533eceb9786b","slug":"dose-initiation-titration","fullItemName":"Dose - initiation and titration","depth":3,"htmlHeader":"<!-- begin field c3d91d17-49e8-4a4a-970d-ff3b2ce20910 --><h3>How should I start and titrate desmopressin?</h3><!-- end field c3d91d17-49e8-4a4a-970d-ff3b2ce20910 -->","summary":"","htmlStringContent":"<!-- begin item c11ba58b-eed9-4d34-9c56-2999592c0b49 --><!-- begin field 476b11a5-478e-418f-aec6-6b5bb736a6e8 --><ul><li><strong>The recommended dose of oral lyophilisate desmopressin (Noqdirna<sup>®</sup>) for idiopathic nocturnal polyuria in men is</strong> 50 micrograms daily taken one hour before bedtime, administered sublingually without water.</li><li><strong>Assess the man's response after a trial of 1–2 weeks' treatment.</strong><ul><li>A dose increase with this product is not recommended in elderly people (age 65 years and older).</li><li>If higher doses are considered for people aged younger than 65 years in case of an insufficient response to Noqdirna<sup>®</sup>, other desmopressin oral lyophilisate products should be used.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2016c</a>]</p><!-- end field 476b11a5-478e-418f-aec6-6b5bb736a6e8 --><!-- end item c11ba58b-eed9-4d34-9c56-2999592c0b49 -->","subChapters":[]},{"id":"37467a17-5c22-5af1-aa7c-1e9eee703c24","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 332d148e-e069-4f9c-805c-2f61acb39654 --><h3>What are the adverse effects of desmopressin?</h3><!-- end field 332d148e-e069-4f9c-805c-2f61acb39654 -->","summary":"","htmlStringContent":"<!-- begin item 39adfb1e-3beb-46ee-9278-a6e36f7ff2a4 --><!-- begin field 59a30e80-46ed-4d2e-a391-09630cab0be6 --><ul><li><strong>Fluid retention and hyponatraemia can occur, leading to headache, nausea and vomiting, weight gain, and convulsions (in serious cases).</strong><ul><li>To reduce the risk of hyponatraemic convulsions, advise the person to:<ul><li>Drink only enough to satisfy their thirst, avoid drinking fluids in the last 1–2 hours before bed, and avoid drinking fluids for 8 hours after taking desmopressin.</li><li>Stop taking desmopressin during periods of diarrhoea or vomiting (until fluid balance is normal).</li><li>Avoid using over-the-counter ibuprofen or aspirin as they may worsen water retention and increase the risk of hyponatraemia.</li></ul></li><li>In the event of signs or symptoms of water retention and/or hyponatremia (headache, nausea/vomiting, weight gain, and, in severe cases, convulsions), treatment should be interrupted and reassessed. If restarting treatment, strict fluid restriction should be enforced and serum sodium levels monitored.</li><li>The risk of hyponatremia is higher in people aged 65 years of age or older.</li></ul></li><li><strong>Other possible adverse effects of desmopressin include:</strong><ul><li>Frequency not known — abdominal pain, allergic dermatitis, and emotional disorder, epistaxis, and nasal congestion.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]</p><!-- end field 59a30e80-46ed-4d2e-a391-09630cab0be6 --><!-- end item 39adfb1e-3beb-46ee-9278-a6e36f7ff2a4 -->","subChapters":[]},{"id":"f91d1475-60eb-5f20-ba14-f297d1fcedfc","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 7a6703cf-1067-43a2-964d-f08199d0c3dd --><h3>What are the key drug interactions of desmopressin?</h3><!-- end field 7a6703cf-1067-43a2-964d-f08199d0c3dd -->","summary":"","htmlStringContent":"<!-- begin item 2484fc69-2e3a-49ae-816d-98bbb069e456 --><!-- begin field 0840aa58-ece5-42e8-948a-b0a6c4b51f88 --><ul><li><strong>Drug interactions of desmopressin include </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li><strong>Drugs known to induce syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH)</strong> — concurrent use of desmopressin and drugs known to induce SIADH (such as tricyclic antidepressants, selective serotonin reuptake inhibitors, chlorpromazine, diuretics, and carbamazepine)<strong> </strong>may cause an increased risk of water retention and/or hyponatremia.<ul><li>If concurrent use cannot be avoided, monitor closely for symptoms of water retention and/or hyponatremia (headache, nausea/vomiting, weight gain, and, in severe cases, convulsions).</li></ul></li><li><strong>Nonsteroidal anti-inflammatory drugs and aspirin </strong>— may potentiate the antidiuretic effect of desmopressin and may induce water retention and/or hyponatremia.<ul><li>If concurrent use cannot be avoided, monitor closely for symptoms of water retention and/or hyponatremia.</li></ul></li><li><strong>Loperamide </strong>— concurrent use with desmopressin may result in a 3-fold increase of desmopressin plasma concentrations following oral administration, which may lead to an increased risk of water retention and/or hyponatremia.<ul><li>If concurrent use cannot be avoided, monitor closely for symptoms of water retention and/or hyponatraemia.</li></ul></li><li><strong>Lithium </strong>— may diminish the antidiuretic effect of desmopressin.<ul><li>Special caution should be exercised in people taking lithium in case of masking of early-stage lithium-induced nephrogenic diabetes insipidus by administration of desmopressin for a nocturia indication.</li><li>Desmopressin is not recommended in people suspected of having lithium-induced nephrogenic diabetes insipidus.</li></ul></li></ul></li><li><strong>For a complete list of possible drug interactions of desmopressin, </strong>see the <a data-hyperlink-id=\"40ec65d5-2d3d-46c6-a3a8-a98f01110425\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"cf6a8caf-9ccd-4adf-9777-a98f0111044b\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><!-- end field 0840aa58-ece5-42e8-948a-b0a6c4b51f88 --><!-- end item 2484fc69-2e3a-49ae-816d-98bbb069e456 -->","subChapters":[]},{"id":"6a7537e5-9b10-570a-ae2b-6844ceefacbc","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field 13229d7d-d3ea-4e74-97cc-36219aeda077 --><h3>How should I monitor a person taking desmopressin?</h3><!-- end field 13229d7d-d3ea-4e74-97cc-36219aeda077 -->","summary":"","htmlStringContent":"<!-- begin item e7ae8018-e06c-4cba-ada7-85762dbabde8 --><!-- begin field 87a2b8a1-cb56-4ae6-bb84-23a03e64ac60 --><ul><li>Elderly people are at increased risk of developing hyponatraemia with desmopressin treatment and may also have impaired renal function.<ul><li>The manufacturer advises that in elderly men (age 65 years and older):<ul><li>Daily doses above 50 micrograms should not be used.</li><li>Serum sodium levels should be monitored before initiating treatment, in the first week of treatment (4–8 days after initiation) and again at one month after treatment initiation. Desmopressin treatment should be discontinued if the serum sodium level falls below the lower limit of normal range (135 mmol/L).</li><li>Treatment should be reviewed if there is no therapeutic benefit after 3 months.</li></ul></li></ul></li><li>Periodic blood pressure and body weight checks are recommended to monitor fluid overload.</li><li>In the event of signs or symptoms of water retention and/or hyponatremia (headache, nausea/vomiting, weight gain, and, in severe cases, convulsions), treatment should be interrupted and reassessed.<ul><li>If restarting treatment strict fluid restriction should be enforced and serum sodium levels monitored.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]</p><!-- end field 87a2b8a1-cb56-4ae6-bb84-23a03e64ac60 --><!-- end item e7ae8018-e06c-4cba-ada7-85762dbabde8 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}